Cryoablation has been found to induce a systemic tumor-specific response, thereby enhancing the tumor’s susceptibility to immunotherapy agents such as checkpoint inhibitors and anti-Her2 antibodies in triple-negative and Her2-positive breast cancer, respectively. The gene discussed is ERBB2; the disease is breast carcinoma.